Trial Profile

A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATV-1601 (Primary) ; Fulvestrant (Primary)
Indications HER2 negative breast cancer; Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
Sponsors Atavistik Bio

Most Recent Events

29 Aug 2025 Status changed from not yet recruiting to recruiting.
04 Aug 2025 According to an Atavistik Bio media release, the company is looking forward to evaluating ATV-1601 in the clinic and moving rapidly toward early proof-of-concept data for this program.
04 Aug 2025 According to an Atavistik Bio media release, first patient has been dosed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com